Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Seres Therapeutics, Inc. has 9 disclosed suppliers and 6 disclosed customers. Each one is named in an SEC filing, either Seres Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A., or SPN, and with certain of its affiliates, collectively, Nestlé Health Science, in September 2024.”
FILING10-K0001193125-26-103276cik 0001609809
“As consideration for the Transaction, SPN agreed to pay us: (i) a cash payment, which was paid at Closing, of $100 million, less approximately $17.9 million owed by us to an affiliate of SPN as of March 31, 2024 under the prior license agreement between us and the SPN affiliate, less approximately CHF 2.0 million in satisfaction of fees due under an existing manufacturing agreement between us and Bacthera; (ii) cash installment payments of $50 million, which was received on January 15, 2025 and $25 million, which was received on July 1, 2025, (offset by $1.4 million paid by us to Nestl é on July 1, 2025 related to certain employment obligations assumed by SPN, as described below), conditioned on our material compliance with obligations under the TSA entered into at Closing between us and NESA; (iii) prepayment of the $60 million Prepaid Milestone tied to the achievement of the First Sales Milestone of worldwide annual net sales of the Product of $150 million, which was paid in cash at Closing, which Prepaid Milestone will accrue interest at a fixed rate of 10% per annum until the First Sales Milestone is achieved and 5% per annum thereafter until the earlier of (x) the date on which the Prepaid Milestone, plus accrued interest thereon, has been repaid in full by set-off and (y) the last day of the Milestone Period; and (iv) future Milestone Payments of (x) $125 million tied to the achievement of worldwide annual net sales of the Product of $400 million and (y) $150 million tied to the achievement of worldwide annual net sales of the Product of $750 million, during the Milestone Period from Closing until December 31 of the calendar year in which the tenth anniversary of Closing occurs.”
FILING10-K0001193125-26-103276cik 0001609809
“The CARB-X grant provides us with up to $3.6 million of funding for research, manufacture, and design of a Phase 1 clinical trial in ICU patients.”
FILING10-K0001193125-26-103276cik 0001609809
“In May 2021, we entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, to sell shares of our common stock with aggregate gross sales proceeds of up to $150.0 million, from time to time, through an "at-the-market" equity offering program under which Cowen acts as sales agent.”
FILING10-K0001193125-26-103276cik 0001609809
“The change in other income (expense), net was primarily due to the $75.0 million of installment payments received from Nestlé in January and July 2025, which were conditioned on our material compliance with obligations under the TSA, an increase of $7.0 million of reimbursement income from Nestlé associated with the performance of TSA services, and $0.6 million increase in sublease income.”
FILING10-K0001193125-26-103276cik 0001609809
“We led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A., or SPN, and with certain of its affiliates, collectively, Nestlé Health Science, in September 2024.”
FILING10-K0001193125-26-103276cik 0001609809
“We have only developed one FDA-approved product, VOWST, which was sold to SPN in September 2024.”
FILING10-K0001193125-26-103276cik 0001609809
“In October 2023, we were awarded a $500,000 grant from the CCF to leverage our clinical results and biological mechanism insights to functionally characterize subpopulations and to define associated biomarkers for IBD patient selection and stratification of patients where the GI microbiome plays an active role in inflammation and could be modified to reduce colitis.”
FILING10-K0001193125-26-103276cik 0001609809
“Development of LBP-LF is ongoing with grant support from CARB-X and in collaboration with Columbia University.”
FILING10-K0001193125-26-103276cik 0001609809
“In May 2021, we entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, to sell shares of our common stock with aggregate gross sales proceeds of up to $150.0 million, from time to time, through an "at-the-market" equity offering program under which Cowen acts as sales agent.”
FILING10-K0001193125-26-103276cik 0001609809
“Interest expense consists of interest incurred under our loan and security agreement, or the Hercules Loan and Security Agreement, with Hercules Capital, Inc., or Hercules.”
FILING10-K0001193125-26-103276cik 0001609809
“We have been collaborating with Memorial Sloan Kettering Cancer Center for over a decade on the impact of the GI microbiome on immune related diseases and cancer; recently this long-standing collaboration included an investigator-sponsored trial, or IST, evaluating SER-155 in 15 participants with irEC.”
FILING10-K0001193125-26-103276cik 0001609809
“Under the TSA with NESA, beginning in the fourth quarter of 2024, we provided certain manufacturing services and related functions of the VOWST Business and operations.”
FILING10-K0001193125-26-103276cik 0001609809
“Of the issued U.S. patents, 13 U.S. patents (including one as licensee) have been assigned to Nestlé Health Science as part of its purchase of VOWST.”
FILING10-K0001193125-26-103276cik 0001609809
“We were obligated to use the proceeds from the completion of the Transaction to fully repay our indebtedness under our prior credit facility with Oaktree Capital Management ("Oaktree").”
FILING10-K0001193125-26-103276cik 0001609809
Watchlist prices, news filtered to it, and its next report on your desk.
Seres Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 4.62 · gapped above the open, then crossed back over prior close. High/low 4.94 at 8:30 am ET, 4.56 at 11:30 am ET.
MCRB (Seres Therapeutics, Inc.) has 9 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.